Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Paediatr Neurol ; 37: 1-7, 2022 Mar.
Article in English | MEDLINE | ID: mdl-34999443

ABSTRACT

Deleterious variants in the transcription factor early B-cell factor 3 (EBF3) are known to cause a neurodevelopmental disorder (EBF3-NDD). We report eleven individuals with EBF3 variants, including an individual with a duplication/triplication mosaicism of a region encompassing EBF3 and a phenotype consistent with EBF3-NDD, which may reflect the importance of EBF3 gene-dosage for neurodevelopment. The phenotype of individuals in this cohort was quite mild compared to the core phenotype of previously described individuals. Although ataxia tended to wane with age, we show that cognitive difficulties may increase, and we recommend that individuals with EBF3-NDD have systematic neuropsychological follow-up.


Subject(s)
Mosaicism , Neurodevelopmental Disorders , Transcription Factors , Ataxia/genetics , Gene Dosage , Humans , Neurodevelopmental Disorders/genetics , Phenotype , Transcription Factors/genetics
2.
Neurol Genet ; 6(4): e444, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32637629

ABSTRACT

OBJECTIVE: To characterize the genetic background of molecularly undefined childhood-onset ataxias in Finland. METHODS: This study examined a cohort of patients from 50 families with onset of an ataxia syndrome before the age of 5 years collected from a single tertiary center, drawing on the advantages offered by next generation sequencing. A genome-wide genotyping array (Illumina Infinium Global Screening Array MD-24 v.2.0) was used to search for copy number variation undetectable by exome sequencing. RESULTS: Exome sequencing led to a molecular diagnosis for 20 probands (40%). In the 23 patients examined with a genome-wide genotyping array, 2 additional diagnoses were made. A considerable proportion of probands with a molecular diagnosis had de novo pathogenic variants (45%). In addition, the study identified a de novo variant in a gene not previously linked to ataxia: MED23. Patients in the cohort had medically actionable findings. CONCLUSIONS: There is a high heterogeneity of causative mutations in this cohort despite the defined age at onset, phenotypical overlap between patients, the founder effect, and genetic isolation in the Finnish population. The findings reflect the heterogeneous genetic background of ataxia seen worldwide and the substantial contribution of de novo variants underlying childhood ataxia.

4.
Neurogenetics ; 19(1): 49-53, 2018 01.
Article in English | MEDLINE | ID: mdl-29350304

ABSTRACT

Mutations in mitochondrial ATP synthase 6 (MT-ATP6) are a frequent cause of NARP (neurogenic muscle weakness, ataxia, and retinitis pigmentosa) or Leigh syndromes, especially a point mutation at nucleotide position 8993. M.8969G>A is a rare MT-ATP6 mutation, previously reported only in three individuals, causing multisystem disorders with mitochondrial myopathy, lactic acidosis, and sideroblastic anemia or IgA nephropathy. We present two siblings with the m.8969G>A mutation and a novel, substantially milder phenotype with lactic acidosis, poor growth, and intellectual disability. Our findings expand the phenotypic spectrum and show that mtDNA mutations should be taken account also with milder, stable phenotypes.


Subject(s)
Acidosis, Lactic/genetics , DNA, Mitochondrial/genetics , Growth Disorders/genetics , Intellectual Disability/genetics , Mitochondrial Proton-Translocating ATPases/genetics , Acidosis, Lactic/complications , Adolescent , Child , Female , Growth Disorders/complications , Humans , Intellectual Disability/complications , Male , Pedigree , Phenotype , Point Mutation , Siblings
5.
Hum Mol Genet ; 26(17): 3352-3361, 2017 09 01.
Article in English | MEDLINE | ID: mdl-28645153

ABSTRACT

Leigh syndrome is a severe infantile encephalopathy with an exceptionally variable genetic background. We studied the exome of a child manifesting with Leigh syndrome at one month of age and progressing to death by the age of 2.4 years, and identified novel compound heterozygous variants in PNPT1, encoding the polynucleotide phosphorylase (PNPase). Expression of the wild type PNPT1 in the subject's myoblasts functionally complemented the defects, and the pathogenicity was further supported by structural predictions and protein and RNA analyses. PNPase is a key enzyme in mitochondrial RNA metabolism, with suggested roles in mitochondrial RNA import and degradation. The variants were predicted to locate in the PNPase active site and disturb the RNA processing activity of the enzyme. The PNPase trimer formation was not affected, but specific RNA processing intermediates derived from mitochondrial transcripts of the ND6 subunit of Complex I, as well as small mRNA fragments, accumulated in the subject's myoblasts. Mitochondrial RNA processing mediated by the degradosome consisting of hSUV3 and PNPase is poorly characterized, and controversy on the role and location of PNPase within human mitochondria exists. Our evidence indicates that PNPase activity is essential for the correct maturation of the ND6 transcripts, and likely for the efficient removal of degradation intermediates. Loss of its activity will result in combined respiratory chain deficiency, and a classic respiratory chain-deficiency-associated disease, Leigh syndrome, indicating an essential role for the enzyme for normal function of the mitochondrial respiratory chain.


Subject(s)
Exoribonucleases/genetics , Exoribonucleases/metabolism , Leigh Disease/genetics , Child, Preschool , Exome , Exoribonucleases/chemistry , Female , Gene Expression , Humans , Infant , Infant, Newborn , Leigh Disease/metabolism , Mitochondria/metabolism , Mitochondrial Diseases/genetics , Polyribonucleotide Nucleotidyltransferase , RNA/metabolism , RNA, Messenger/metabolism , RNA, Mitochondrial
SELECTION OF CITATIONS
SEARCH DETAIL
...